Editing Biodefense (section)

== Biodefense market ==
In 2015, global biodefense market was estimated at $9.8 billion. Experts correlated the large marketplace to an increase in government attention and support as a result of rising bioterrorism threats worldwide. Government's heightened interest is anticipated expand the industry into the foreseeable future. According to Medgadget.com, "Many government legislations like [[Project Bioshield Act|Project Bioshield]] offers nations with counter measures against [[CBRN defense|chemical, radiological, nuclear and biological attack]]."<ref name=":0">{{Cite web|url=http://www.medgadget.com/2016/09/biodefense-market-size-worth-17bn-by-2024.html|title=Biodefense Market size worth $17bn by 2024|date=2016-09-26|website=Medgadget.com|language=en-US|access-date=2016-10-03|archive-url=https://web.archive.org/web/20161005085831/http://www.medgadget.com/2016/09/biodefense-market-size-worth-17bn-by-2024.html|archive-date=2016-10-05|url-status=dead}}</ref>

Project Bioshield offers accessible biological countermeasures targeting various strains of smallpox and anthrax. "Main goal of the project is creating funding authority to build next generation counter measures, make innovative research & development programs and create a body like FDA (Food & Drug Administration) that can effectively use treatments in case of emergencies."<ref name=":0" /> Increased funding, in addition to public health organizations' elevated consideration in biodefense technology investments, could trigger growth in the global biodefense market.<ref name=":0" />

The global biodefense market is divided into geographical locations such as APAC, Latin America, Europe, MEA, and North America. The biodefense industry in North America lead the global industry by a large margin, making it the highest regional revenue share for 2015, contributing approximately $8.91 billion of revenue this year, due to immense funding and government reinforcements. The biodefense market in Europe is predicted to register a CAGR of 11.41% by the forecast timeline. The United Kingdom's Ministry of Defense granted $75.67 million designated for defense & civilian research, making it the highest regional industry share for 2012.<ref name=":0" />

In 2016, Global Market Insights released a report covering the new trends in the biodefense market backed by detailed, scientific data. Industry leaders in biodefense market include the following corporations: [[Emergent BioSolutions|Emergent Biosolutions]], [[SIGA Technologies]], Ichor Medical Systems Incorporation, PharmaAthene, Cleveland BioLabs Incorporation, Achaogen (bankrupt in 2019<ref name="Jacobs">{{cite news |last1=Jacobs |first1=Andrew |title=Crisis Looms in Antibiotics as Drug Makers Go Bankrupt |url=https://www.nytimes.com/2019/12/25/health/antibiotics-new-resistance.html |access-date=23 November 2022 |work=The New York Times |date=25 December 2019 |language=en}}</ref>), Alnylam Pharmaceuticals, Avertis,<ref>{{Cite web|url=http://surturian.com|title=Next Generation Biodefense|date=2021-02-20|website=Surturian.com|language=en-US|access-date=2021-02-20}}</ref> Xoma Corporation, Dynavax Technologies Incorporation, Elusys Therapeutics, DynPort Vaccine Company LLC, [[Bavarian Nordic]] and Nanotherapeutics Incorporation.<ref name=":0" />